Artelo Biosciences ARTL
NASDAQ ARTL
$4.08 +0.01 (+0.25%)
As of: Sep 30, 2026 · 3:59 PM EDT

Artelo Biosciences (ARTL) Convertible Debt (2025)

Updated

Artelo Biosciences' Convertible Debt came in at $609,000 for Q4 2025, down 30.4% from the prior quarter.

Analysis

Artelo Biosciences (ARTL) Convertible Debt (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Artelo Biosciences 81,090.68 -5.05 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 609,000.00
Sep 30, 2025 875,000.00
Jun 30, 2025 791,000.00
API Access

Artelo Biosciences Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ARTL&period=max&api_key=YOUR_API_KEY